We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

MedXY Editorial Team•Sep 18, 2026•Hematology-Oncology
Large B-Cell LymphomaCAR T-cell therapyTRANSCEND NHL 001long-term survivalLisocabtagene Maraleucel

Highlight

  • Lisocabtagene maraleucel (liso-cel) yields a median overall survival of 27.5 months in relapsed or refractory large B-cell lymphoma (R/R LBCL) patients.
  • Estimated five-year overall survival (OS) reaches 38% in efficacy-evaluable patients, supporting durable responses.
  • Disease-specific survival (DSS) estimates at five years show even higher rates, suggesting sustained control of lymphoma-related mortality.
  • Long-term follow-up reveals no new safety concerns, with low rates of late severe infections and second primary malignancies, underscoring a favorable safety profile.

Study Background and Disease Burden

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter AnalysisBridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safSep 13, 2026Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple MyelomaArlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including prSep 12, 2026Impact of Severe Anastomotic Leak After Esophagectomy on Long-Term Survival: Insights from a Modern Multicenter CohortA large European study shows that severe anastomotic leaks requiring surgical reintervention after esophagectomy significantly reduce long-term survival and increase postoperative mortality, underscoring the need for targeted management strSep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Sep 6, 2026
Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal CancersCAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.Aug 29, 2026
Immunosenescence as a Key Barrier to CD19 CAR T-Cell Therapy in Chronic Lymphocytic LeukemiaThis article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.Aug 27, 2026